Company research
RedHill Biopharma Ltd.
CIK 1553846Updated Sep 24, 2026
SecurityRDHL · NASDAQ · adr
RDHL price & chart
Loading TradingView…
NASDAQ:RDHL on TradingView ↗About the company
We are a specialty biopharmaceutical company, primarily focused on GI, infectious diseases, medical countermeasures and oncology. Our primary goal is to become a leading specialty biopharmaceutical company.
In the news
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement News provided by RedHill Biopharma Ltd. Dec 01, 2025, 07:00 ET Share this article Share to X Share this article Share to X TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharm ↗
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -8,268,000Source | 23,916,000Source | -71,669,000Source | -97,744,000Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | 52,000Source | 31,930,000Source | -2,845,000Source | -3,021,000Source |
| AdjustmentsForFinanceCostsUSD | — | — | 958,000Source | — |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | -2,110,000Source | -952,000Source | -7,434,000Source | 111,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 665,000Source | 1,647,000Source | 5,675,000Source | 10,212,000Source |
| IncreaseDecreaseInWorkingCapitalUSD | -2,053,000Source | 15,619,000Source | -8,008,000Source | 1,153,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 636,000Source | 1,175,000Source | 1,475,000Source | 1,683,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 9,567,000Source | 16,219,000Source | 28,586,000Source | 32,365,000Source |
| Total RevenueUSD | 8,043,000Source | 6,530,000Source | 61,800,000Source | 85,757,000Source |
| Additional Financial Items | ||||
| BasicEarningsLossPerShareUSD per share | 0Source | 0.01Source | -0.12Source | -0.21Source |
| DepreciationRightofuseAssetsUSD | 521,000Source | 1,276,000Source | 1,869,000Source | 1,890,000Source |
| DilutedEarningsLossPerShareUSD per share | 0Source | 0.01Source | -0.12Source | -0.21Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 665,000Source | — | — | — |
| FinanceCostsUSD | 2,056,000Source | 9,605,000Source | 42,387,000Source | 16,660,000Source |
| FinanceIncomeUSD | 8,401,000Source | 20,889,000Source | 13,562,000Source | 51,000Source |
| GrossProfitUSD | 4,851,000Source | 3,071,000Source | 28,463,000Source | 36,351,000Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | — | — | 0Source | — |
| InterestExpenseOnLeaseLiabilitiesUSD | 55,000Source | 367,000Source | 430,000Source | 397,000Source |
| OtherFinanceCostUSD | 473,000Source | 61,000Source | 56,000Source | 65,000Source |
| OtherIncomeUSD | — | 210,000Source | — | — |
| OtherOperatingIncomeExpenseUSD | -2,359,000Source | 44,064,000Source | — | — |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | 156,000Source | 206,000Source | 261,000Source | 285,000Source |
| ProfitLossFromOperatingActivitiesUSD | -14,613,000Source | 12,632,000Source | -42,844,000Source | -81,135,000Source |
| ResearchAndDevelopmentExpenseUSD | 1,588,000Source | 3,528,000Source | 7,279,000Source | 29,498,000Source |